Quick Answer
Choline Sleep Quality Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: 1 2 3–6 7 8 9 10–12 13 14 Hyperlipidemia (HLP) refers to a systemic lipid metabolism abnormality characterized by elevated levels of total cholesterol (TC), triglycerides (TG), and/or low-density lipoprotein cholesterol (LDL-C), and/or reduced levels of high-density lipoprotein cholesterol (HDL-C) in the plasma due to various causes.
Key Takeaways
- 011 2 3–6 7 8 9 10–12 13 14 Hyperlipidemia (HLP) refers to a systemic lipid metabolism abnormality characterized by elevated levels of total cholesterol (TC), triglycerides (TG), and/or low-density lipoprotein cholesterol (LDL-C), and/or reduced levels of high-density lipoprotein cholesterol (HDL-C) in the plasma due to various causes. [Xie Haihua (2026)]
- 02HLP, particularly elevated LDL-C levels, has been established as a risk factor for cardiovascular diseases and cognitive disorders (CD) [,]. [Xie Haihua (2026)]
- 03It has been reported that alterations in plasma lipid profiles appear to exacerbate cognitive decline, thereby increasing the risk of developing Alzheimer’s disease in non-demented elderly individuals []. [Xie Haihua (2026)]
- 04While intrinsic genetic factors drive much of this neurodevelopment, emerging evidence highlights the influence of extrinsic factors, particularly gut health, sleep architecture, and nutrition [,]. [Chaturvedi Devyani (2026)]
The current Migaku evidence database contains 2 reusable source documents for Choline Sleep Quality Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation.
- 1 2 3–6 7 8 9 10–12 13 14 Hyperlipidemia (HLP) refers to a systemic lipid metabolism abnormality characterized by elevated levels of total cholesterol (TC), triglycerides (TG), and/or low-density lipoprotein cholesterol (LDL-C), and/or reduced levels of high-density lipoprotein cholesterol (HDL-C) in the plasma due to various causes. [Xie Haihua (2026); evidence level 2]
- HLP, particularly elevated LDL-C levels, has been established as a risk factor for cardiovascular diseases and cognitive disorders (CD) [,]. [Xie Haihua (2026); evidence level 2]
- It has been reported that alterations in plasma lipid profiles appear to exacerbate cognitive decline, thereby increasing the risk of developing Alzheimer’s disease in non-demented elderly individuals []. [Xie Haihua (2026); evidence level 2]
- While intrinsic genetic factors drive much of this neurodevelopment, emerging evidence highlights the influence of extrinsic factors, particularly gut health, sleep architecture, and nutrition [,]. [Chaturvedi Devyani (2026); evidence level 3]
- However, disruptions in this process may result from factors such as cesarean delivery, antibiotic exposure, early-life stress, or diets lacking key nutrients and probiotics that favorably modulate the gut microbiota, thereby directly impacting neurodevelopmental outcomes. [Chaturvedi Devyani (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources